Browse by Medical Category
David M. Langenau, PhD
Associate Professor of Pathology, Harvard Medical School
Associate Chief of Pathology (Research), Massachusetts General HospitalDirector, Molecular Pathology Unit, Massachusetts General HospitalMember, MGH Cancer Center and Center for Regenerative Medicine
Massachusetts General HospitalMolecular Pathology Unit149 13th Street, 6th FloorCharlestown, MA 02129Phone: firstname.lastname@example.org
The Langenau laboratory research focus is to uncover relapse mechanisms in pediatric cancer. Utilizing zebrafish models of embryonal rhabdomysoarcoma (ERMS) and T-cell acute lymphoblastic leukemia (T-ALL), we have undertaken chemical and genetic approaches to identify novel modulators of progression, therapy-resistance, and relapse.
Visualizing and killing cancer stem cells in embryonal rhabdomyosarcoma
ERMS is a common soft-tissue sarcoma of childhood and phenotypically recapitulates fetal muscle development arrested at early stages of differentiation. Microarray and cross-species comparisons of zebrafish, mouse and human ERMS uncovered that the RAS pathway is activated in a majority of ERMS. Building on this discovery, our laboratory has developed a transgenic zebrafish model of RAS-induced ERMS that mimics the molecular underpinnings of human ERMS. We used fluorescent transgenic zebrafish to label functionally distinct tumor cells. Specifically, the myf5-GFP+ self-renewing cancer stem cells drive continued tumor growth at relapse and are molecularly similar to non-transformed, activated muscle satellite cells.
Building on the dynamic live cell imaging approaches available in the zebrafish ERMS model, our laboratory has uncovered a number of molecular pathways that drive continued tumor growth and progression by regulating cancer stem cell function. Finally, using chemical genetic approaches, we have identified drugs that kill relapse-associated, self-renewing ERMS cells. We are currently assessing the genetic pathways uncovered by our work and a subset of drugs for their ability to regulate growth of patient-derived xenografts.
Uncovering progression-associated driver mutations in T-cell acute lymphoblastic leukemia
T-ALL is an aggressive malignancy of thymocytes that affects thousands of children and adults in the United States each year. Recent advancements in conventional chemotherapies have improved the five-year survival rate of patients with T-ALL. However, patients with relapse disease are largely unresponsive to additional therapy and have a poor prognosis. Ultimately, 70% of children and 92% of adults will die of relapse T-ALL, underscoring the clinical imperative for identifying the molecular mechanisms that cause leukemia cells to re-emerge at relapse.
Utilizing a novel zebrafish model of relapse T-ALL, large-scale trangenesis platforms, and unbiased bioinformatic approaches, we have uncovered new oncogenic drivers associated with aggression, therapy resistance and relapse. A large subset of these genes exerts an important role in regulating human T-ALL proliferation, apoptosis and response to therapy. Discovering novel relapse-driving oncogenic pathways will likely identify new drug targets for the treatment of T-ALL.
Read more about the Langenau Lab from the Center for Cancer Research Annual Report and the Pathology Basic Science Research Brochure.
Elaine Garcia* Madeline Hayes, PhD David M. Langenau, PhD Mariana Lobato de Oliveira*Karin McCarthy John Moore, PhD Ashwin Ramakrishnan Qin Tang* Ines Tenente* Alessandra Welker, PhD
Complete Bibliography of David M. Langenau via PubMed
Hayes MN, McCarthy K, Jin A, Oliveira ML, Iyer S, Garcia SP, Sindiri S, Gryder B, Motala Z, Nielsen GP, Borg JP, van de Rijn M, Malkin D, Khan J, Ignatius MS, Langenau DM. Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. Cell Stem Cell. 2018; 22(3):414-427.
Lobbardi R, Pinder J, Martinez-Pastor B, Theodorou M, Blackburn JS, Abraham BJ, Namiki Y, Mansour M, Abdelfattah NS, Molodtsov A, Alexe G, Toiber D, de Waard M, Jain E, Boukhali M, Lion M, Bhere D, Shah K, Gutierrez A, Stegmaier K, Silverman LB, Sadreyev RI, Asara JM, Oettinger MA, Haas W, Look AT, Young RA, Mostoslavsky R, Dellaire G, Langenau DM. TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2017; 7(11):1336-1353.
Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Qin Tang, John C. Moore, Myron S. Ignatius, Inês M. Tenente, Madeline N. Hayes, Elaine G. Garcia, Nora Torres Yordán, Caitlin Bourque, Shuning He, Jessica S. Blackburn, A. Thomas Look, Yariv Houvras, David M. Langenau. Nat Commun. 2016; 7: 10358.
Clonal evolution enhances leukemia propagating cell frequency in T-cell acute lymphoblastic leukemia through Akt/mTORC1 pathway activation Jessica S. Blackburn, Sali Liu, Jayme L. Wilder, Kimberly P. Dobrinski, Riadh Lobbardi, Finola E. Moore, Sarah A. Martinez, Eleanor Y. Chen, Charles Lee, David M. Langenau. Cancer Cell. 2014 Mar 17; 25(3): 366–378.
In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Myron S. Ignatius, Eleanor Chen, Natalie M. Elpek, Adam Fuller, Inês M. Tenente, Ryan Clagg, Sali Liu, Jessica S. Blackburn, Corinne M. Linardic, Andrew Rosenberg, Petur G. Nielsen, Thorsten R. Mempel, David M. Langenau. Cancer Cell. 2012 May 25; 21(5): 680–693.
Massachusetts General Hospital
Back to Top